200 related articles for article (PubMed ID: 21920027)
1. Kinetic analyses of Keap1-Nrf2 interaction and determination of the minimal Nrf2 peptide sequence required for Keap1 binding using surface plasmon resonance.
Chen Y; Inoyama D; Kong AN; Beamer LJ; Hu L
Chem Biol Drug Des; 2011 Dec; 78(6):1014-21. PubMed ID: 21920027
[TBL] [Abstract][Full Text] [Related]
2. Optimization of fluorescently labeled Nrf2 peptide probes and the development of a fluorescence polarization assay for the discovery of inhibitors of Keap1-Nrf2 interaction.
Inoyama D; Chen Y; Huang X; Beamer LJ; Kong AN; Hu L
J Biomol Screen; 2012 Apr; 17(4):435-47. PubMed ID: 22156223
[TBL] [Abstract][Full Text] [Related]
3. Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1).
Bresciani A; Missineo A; Gallo M; Cerretani M; Fezzardi P; Tomei L; Cicero DO; Altamura S; Santoprete A; Ingenito R; Bianchi E; Pacifici R; Dominguez C; Munoz-Sanjuan I; Harper S; Toledo-Sherman L; Park LC
Arch Biochem Biophys; 2017 Oct; 631():31-41. PubMed ID: 28801166
[TBL] [Abstract][Full Text] [Related]
4. Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling.
Lo SC; Li X; Henzl MT; Beamer LJ; Hannink M
EMBO J; 2006 Aug; 25(15):3605-17. PubMed ID: 16888629
[TBL] [Abstract][Full Text] [Related]
5. Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model.
Tong KI; Katoh Y; Kusunoki H; Itoh K; Tanaka T; Yamamoto M
Mol Cell Biol; 2006 Apr; 26(8):2887-900. PubMed ID: 16581765
[TBL] [Abstract][Full Text] [Related]
6. Kinetic, thermodynamic, and structural characterizations of the association between Nrf2-DLGex degron and Keap1.
Fukutomi T; Takagi K; Mizushima T; Ohuchi N; Yamamoto M
Mol Cell Biol; 2014 Mar; 34(5):832-46. PubMed ID: 24366543
[TBL] [Abstract][Full Text] [Related]
7. Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1.
Unni S; Deshmukh P; Krishnappa G; Kommu P; Padmanabhan B
FEBS J; 2021 Mar; 288(5):1599-1613. PubMed ID: 32672401
[TBL] [Abstract][Full Text] [Related]
8. Peptide inhibitors of the Keap1-Nrf2 protein-protein interaction.
Hancock R; Bertrand HC; Tsujita T; Naz S; El-Bakry A; Laoruchupong J; Hayes JD; Wells G
Free Radic Biol Med; 2012 Jan; 52(2):444-51. PubMed ID: 22107959
[TBL] [Abstract][Full Text] [Related]
9. Recapitulating the Binding Affinity of Nrf2 for KEAP1 in a Cyclic Heptapeptide, Guided by NMR, X-ray Crystallography, and Machine Learning.
Ortet PC; Muellers SN; Viarengo-Baker LA; Streu K; Szymczyna BR; Beeler AB; Allen KN; Whitty A
J Am Chem Soc; 2021 Mar; 143(10):3779-3793. PubMed ID: 33683866
[TBL] [Abstract][Full Text] [Related]
10. Development of a steady-state FRET-based assay to identify inhibitors of the Keap1-Nrf2 protein-protein interaction.
Schaap M; Hancock R; Wilderspin A; Wells G
Protein Sci; 2013 Dec; 22(12):1812-9. PubMed ID: 24130096
[TBL] [Abstract][Full Text] [Related]
11. Prediction of Binding Energy of Keap1 Interaction Motifs in the Nrf2 Antioxidant Pathway and Design of Potential High-Affinity Peptides.
Karttunen M; Choy WY; Cino EA
J Phys Chem B; 2018 Jun; 122(22):5851-5859. PubMed ID: 29745220
[TBL] [Abstract][Full Text] [Related]
12. Rational cyclization-based minimization of entropy penalty upon the binding of Nrf2-derived linear peptides to Keap1: A new strategy to improve therapeutic peptide activity against sepsis.
Chen K; Huang L; Shen B
Biophys Chem; 2019 Jan; 244():22-28. PubMed ID: 30465941
[TBL] [Abstract][Full Text] [Related]
13. Structural insights into the similar modes of Nrf2 transcription factor recognition by the cytoplasmic repressor Keap1.
Padmanabhan B; Tong KI; Kobayashi A; Yamamoto M; Yokoyama S
J Synchrotron Radiat; 2008 May; 15(Pt 3):273-6. PubMed ID: 18421157
[TBL] [Abstract][Full Text] [Related]
14. p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription.
Jain A; Lamark T; Sjøttem E; Larsen KB; Awuh JA; Øvervatn A; McMahon M; Hayes JD; Johansen T
J Biol Chem; 2010 Jul; 285(29):22576-91. PubMed ID: 20452972
[TBL] [Abstract][Full Text] [Related]
15. A systematic molecular dynamics approach to the study of peptide Keap1-Nrf2 protein-protein interaction inhibitors and its application to p62 peptides.
Lu MC; Yuan ZW; Jiang YL; Chen ZY; You QD; Jiang ZY
Mol Biosyst; 2016 Apr; 12(4):1378-87. PubMed ID: 26935067
[TBL] [Abstract][Full Text] [Related]
16. Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response.
Tong KI; Padmanabhan B; Kobayashi A; Shang C; Hirotsu Y; Yokoyama S; Yamamoto M
Mol Cell Biol; 2007 Nov; 27(21):7511-21. PubMed ID: 17785452
[TBL] [Abstract][Full Text] [Related]
17. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer.
Padmanabhan B; Tong KI; Ohta T; Nakamura Y; Scharlock M; Ohtsuji M; Kang MI; Kobayashi A; Yokoyama S; Yamamoto M
Mol Cell; 2006 Mar; 21(5):689-700. PubMed ID: 16507366
[TBL] [Abstract][Full Text] [Related]
18. Development of an enzyme-linked immunosorbent assay for Keap1-Nrf2 interaction inhibitors identification.
Wang Y; Xiao CY; Lin HQ; Hu JS; Ip TM; Chi-Cheong Wan D
Redox Biol; 2020 Jul; 34():101573. PubMed ID: 32422542
[TBL] [Abstract][Full Text] [Related]
19. New insights into the mechanism of Keap1-Nrf2 interaction based on cancer-associated mutations.
Cheng L; Wang H; Li S; Liu Z; Wang C
Life Sci; 2021 Oct; 282():119791. PubMed ID: 34229009
[TBL] [Abstract][Full Text] [Related]
20. Emerging Substrate Proteins of Kelch-like ECH Associated Protein 1 (Keap1) and Potential Challenges for the Development of Small-Molecule Inhibitors of the Keap1-Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Protein-Protein Interaction.
Zhang Y; Shi Z; Zhou Y; Xiao Q; Wang H; Peng Y
J Med Chem; 2020 Aug; 63(15):7986-8002. PubMed ID: 32233486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
